Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: What are the risks?

Therapeutic Advances in Musculoskeletal Disease

Volumn 7, Issue 1, 2015, Pages 11-16

  Clark, Emma M ^a   Durup, Darshana ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

adverse events; anti osteoporosis medications; bisphosphonates; inflammatory eye reactions; osteoporosis; pathogenesis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CIDOFOVIR; CLODRONIC ACID; COTRIMOXAZOLE; DENOSUMAB; DIETHYLCARBAMAZINE; ETIDRONIC ACID; GAMMA INTERFERON; IBANDRONIC ACID; INTERLEUKIN 6; METIPRANOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; RALOXIFENE; RIFABUTIN; RISEDRONIC ACID; STRONTIUM; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ANKYLOSING SPONDYLITIS; EYE INFLAMMATION; HUMAN; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY EYE REACTION; OSTEOPOROSIS; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SARCOIDOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UVEITIS;

EID: 84922155743     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X14566424     Document Type: Review

References (26)

1. ADRAC (Adverse Drug Reactions Advisory Committee) (2004) Bisphosphonates and ocular information. Australian Adverse Drug Reactions Bulletin, Vol. 23, No. 2. Canberra: Therapeutic Goods Administration.
2. Adami S. Bhalla A. Dorizzi R. Montesanti F. Rosini S. Salvagno G. (1987) The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41: 326–331.
3. Afshari N. Afshari M. Foster C. (2001) Inflammatory conditions of the eye associated with rheumatic diseases. Curr Rheumatol Rep 3: 453–458.
4. Brixen K. Christensen P. Ejersted C. Langdahl B. (2004) Teriparatide (biosynthetic human parathyroid hormone 1–34: a new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol 94: 260–270.
5. Etminan M. Forooghian F. Maberley D. (2012) Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. Can Med Assoc J 184: E431–E434.
6. Fraunfelder F.W. Fraunfelder F.T. (2004) Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 111: 1275–1279.
7. French D. Margo C. (2008) Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina 28: 889–893.
8. Gallacher S. Ralston S. Patel U. Boyle I. (1989) Side-effects of pamidronate. Lancet 8653: 42–43.
9. Kunzmann V. Bauer E. Feurle J. Weissinger F. Tony H. Wilhelm M. (2000) Stimulation of gamma/delta T cells by aminobisphosphonates and induction of anti-plasma cell activity in multiple myeloma. Blood 96: 384–392.
10. Kunzmann V. Bauer E. Wilhelm M. (1999) Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340: 737–738.
11. Mondelo N. Peluffo V. Parma M. Cointry G. Capozza R. Dferretti J. (1997) Preclinical toxicology of bisphosphonates. Medicina 57: 93–100.
12. Neuprez A. Hiligsmann M. Scholtissen S. Bruyere O. Reginster J. (2008) Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Adv Ther 12: 1235–1256.
13. Olevsky O. Martino S. (2008) Randomized Clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women. Menopause: 15: 790–796.
14. Pazianas M. Clark E. Eiken P. Brixen K. Abrahamsen B. (2013) Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database. J Bone Miner Res 28: 455–463.
15. Peterson J. Bedrossian E. (2012) Bisphosphonate-associated orbital inflammation – a case report and review. Orbit 31: 119–123.
16. Sauty A. Pecherstorfer M. Zimmer-Roth I. Fioroni P. Juillerat M. (1996) Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonate treatment in vitro and patients with malignancy. Bone 18: 133–139.
17. Serrano A. Begona L. Anitua E. Cobos R. Orive G. (2013) Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. Gynaecol Endocrinol 29: 1005–1014.
18. Silva-Fernandez L. Rosario M. Martinez-Lopez J. Carmona L. Loza E. (2013) Denosumab for the treatment of osteoporosis: a systematic literature review. Reumatol Clin 9: 42–52.
19. Tanaka Y. Morita C. Tanaka Y. Nieves E. Brenner M. Bloom B. (1995) Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375: 155–158.
20. Tanaka Y. Sano S. Nieves E. de Libero G. Rosa D. Modlin R. (1994) Nonpeptide ligands for human gamma delta T Cells. Proc Natl Acad Sci U S A 91: 8175–8179.
21. Thiebaud D. Sauty A. Burckhardt P. Leuenberger P. Sitzler L. Green J. (1997) An in-vitro and in-vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61: 386–392.
22. Thompson K. Dunford J. Ebetino F. Rogers M. (2002) Identification of a bisphosphonate that inhibits isopentenyldiphosphate isomerase and farnesyl diphosphate synthase. Biochem Biophys Res Commun 290: 869–873.
23. Thompson K. Rogers M. (2006) Bisphosphonates and gamma delta T cells: new insights into old drugs. Bonekey Osteovision 3: 5–13.
24. van Beek E. Pieterman E. Cohen L. Lowik C. Papapoulos S. (1999) Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264: 108–111.
25. Wells G. Cranney A. Peterson J. Boucher M. Shea B. Welch V. et al. (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (review). Cochrane Database Syst Rev. DOI: 10.1002/14651858.CD14004523.pub14651853.
26. Zojer N. Keck A. Pecherstorfer M. (1999) Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 21: 389–406.